Virbac has launched Stelfonta, a novel injectable solution to treat mastocytoma in dogs.

Stelfonta is licensed for the treatment of non-resectable, non-metastatic (WHO staging¹) subcutaneous mast cell tumours (MCTs) located at or distal to the elbow or…

Virbac is hosting two complimentary ‘Seeing is Believing’ CPD webinars alongside the launch of Stelfonta, its new injectable treatment for mast cell tumours in dogs. 

On Tuesday 8^th September Dr Owen Davies, an RCVS and American Specialist in…

Virbac, the maker of Stelfonta, the new intratumoural treatment for mast cell tumours in dogs, has launched three free interactive online CPD modules.

The modules, which are presented by US veterinary oncology specialists Dr Chad Johannes and Dr Sue Ettinger…

Virbac has launched a toolkit to help veterinary practices educate pet owners about the importance of checking their pet for abnormal lumps and bumps. 

The toolkit contains everything a practice needs to create its own lumps and bumps awareness campaign…

Virbac, manufacturer of Stelfonta, has announced that it will host a series of free webinars on the diagnosis of canine mast cell tumours, in collaboration with BattLab/Laboklin.

The webinars will be presented by specialists in their respective fields;…

Virbac, maker of Stelfonta, has released the result of a quick poll of vets at the London Vet Show who said that on average, they had diagnosed 7.03 mast cell tumours (MCTs) in the last year, when earlier research had showed the figure should be more…

Virbac, maker of Stelfonta, the intratumoural solution to treat mast cell tumours in dogs, is hosting a livestream interactive talk with guest speaker Dr Gerry Polton (RCVS & European Specialist in Veterinary Oncology) on 17th May at 8:00pm.

Virbac points…